Profile data is unavailable for this security.
About the company
Vimian Group AB is a Sweden-based veterinary company. The Company is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The Company invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.
- Revenue in SEK (TTM)4.05bn
- Net income in SEK2.94m
- Incorporated2020
- Employees1.10k
- LocationVimian Group ABRiddargatan 19STOCKHOLM 114 57SwedenSWE
- Websitehttps://vimian.com/
More ▼
Mergers & acquisitions
| Acquired company | VIMIAN:STO since announced | Transaction value |
|---|---|---|
| iM3 Dental Ltd | 2.91% | -- |
Data delayed at least 15 minutes, as of Nov 25 2024 14:47 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedencare AB (publ) | 2.47bn | 76.20m | 7.35bn | 559.00 | 96.40 | 0.9564 | 18.82 | 2.97 | 0.4801 | 0.4801 | 15.58 | 48.39 | 0.2428 | 2.26 | 8.69 | 5,087,037.00 | 0.7483 | 1.38 | 0.7727 | 1.43 | 56.76 | 55.34 | 3.08 | 5.10 | 1.67 | 2.42 | 0.1726 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 1.36bn | 336.82m | 10.31bn | 222.00 | 31.73 | 6.61 | 25.27 | 7.61 | 3.33 | 3.33 | 13.42 | 16.01 | 0.6442 | -- | -- | 6,455,538.00 | 16.00 | 15.47 | 17.73 | 16.93 | 73.59 | 73.30 | 24.85 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Vimian Group AB | 4.05bn | 2.94m | 22.59bn | 1.10k | 8,834.69 | 2.97 | 57.36 | 5.58 | 0.0049 | 0.0049 | 8.25 | 14.67 | 0.3401 | 2.85 | 6.75 | 3,678,284.00 | 0.0938 | -- | 0.1025 | -- | 46.88 | -- | 0.2758 | -- | 2.18 | 2.06 | 0.2734 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
| Bonesupport Holding AB | 814.46m | 90.58m | 23.69bn | 131.00 | 264.20 | 36.29 | 234.31 | 29.09 | 1.36 | 1.36 | 12.29 | 9.92 | 1.16 | 0.6138 | 5.62 | 7,756,762.00 | 12.85 | -9.08 | 14.98 | -11.28 | 92.43 | 90.25 | 11.12 | -11.65 | 3.50 | -- | 0.0222 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 9.36bn | 1.72bn | 24.12bn | 1.61k | 13.82 | 1.45 | 9.09 | 2.58 | 14.36 | 14.36 | 78.05 | 136.86 | 0.4439 | 1.47 | 5.52 | 4,401,443.00 | 8.18 | 1.21 | 10.46 | 1.48 | 52.38 | 53.72 | 18.43 | 4.06 | 0.976 | -- | 0.0106 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Camurus AB | 1.69bn | 266.21m | 33.70bn | 249.00 | 128.79 | 10.83 | 119.83 | 19.95 | 4.45 | 4.45 | 28.86 | 52.92 | 0.6246 | 1.03 | 5.83 | 7,929,653.00 | 9.84 | -1.13 | 11.34 | -1.41 | 92.38 | 90.05 | 15.76 | -1.63 | 7.91 | -- | 0.0059 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 8.30bn | 1.21bn | 49.51bn | 2.80k | 44.12 | 6.90 | 29.43 | 5.96 | 3.59 | 3.59 | 24.40 | 22.97 | 0.7849 | 1.29 | 6.39 | 1,906,162.00 | 11.45 | 3.50 | 13.84 | 4.37 | 63.94 | 60.66 | 14.58 | 5.07 | 1.47 | 32.26 | 0.0911 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 16.43bn | 3.82bn | 73.28bn | 3.82k | 19.19 | 6.87 | 16.29 | 4.46 | 2.36 | 2.36 | 10.16 | 6.58 | 0.9593 | 1.53 | 6.94 | 393,502.20 | 22.25 | 19.47 | 28.25 | 24.16 | 59.89 | 59.38 | 23.19 | 20.71 | 1.41 | 143.69 | 0.2174 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Swedish Orphan Biovitrum AB (publ) | 25.44bn | 3.51bn | 103.24bn | 1.81k | 28.83 | 2.68 | 14.34 | 4.06 | 10.06 | 10.06 | 72.98 | 108.01 | 0.3443 | 1.37 | 5.72 | 14,353,840.00 | 4.75 | 5.93 | 5.85 | 7.60 | 78.60 | 77.42 | 13.81 | 16.61 | 0.6225 | 4.35 | 0.325 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Data as of Nov 25 2024. Currency figures normalised to Vimian Group AB's reporting currency: Swedish Krona SEK
17.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Oct 2024 | 19.38m | 3.75% |
| AMF Fonder ABas of 18 Sep 2023 | 14.03m | 2.71% |
| Danica Pension, Livsforsikringsaktieselskabas of 31 Dec 2023 | 11.93m | 2.31% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 10.81m | 2.09% |
| Swedbank Robur Fonder ABas of 31 Oct 2024 | 9.72m | 1.88% |
| SEB Investment Management ABas of 31 Oct 2024 | 7.35m | 1.42% |
| Fj�rde AP-fondenas of 30 Jun 2024 | 6.23m | 1.21% |
| Amundi Asset Management SA (Investment Management)as of 06 Nov 2024 | 3.39m | 0.66% |
| Case Kapitalf�rvaltning ABas of 31 Aug 2024 | 2.90m | 0.56% |
| Oddo BHF Asset Management SASas of 31 Oct 2024 | 2.16m | 0.42% |
More ▼
Data from 28 Jun 2024 - 20 Nov 2024Source: FactSet Research Systems Inc.
